These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 32843442)

  • 21. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.
    Bischof M; Lorenzi M; Lee J; Druyts E; Balijepalli C; Dabbous O
    Curr Med Res Opin; 2021 Oct; 37(10):1719-1730. PubMed ID: 34236007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Onasemnogene abeparvovec for the treatment of spinal muscular atrophy.
    McMillan HJ; Proud CM; Farrar MA; Alexander IE; Muntoni F; Servais L
    Expert Opin Biol Ther; 2022 Sep; 22(9):1075-1090. PubMed ID: 35437095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Onasemnogene Abeparvovec: First Global Approval.
    Hoy SM
    Drugs; 2019 Jul; 79(11):1255-1262. PubMed ID: 31270752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2024 update: European consensus statement on gene therapy for spinal muscular atrophy.
    Kirschner J; Bernert G; Butoianu N; De Waele L; Fattal-Valevski A; Haberlova J; Moreno T; Klein A; Kostera-Pruszczyk A; Mercuri E; Quijano-Roy S; Sejersen T; Tizzano EF; van der Pol WL; Wallace S; Zafeiriou D; Ziegler A; Muntoni F; Servais L
    Eur J Paediatr Neurol; 2024 Jul; 51():73-78. PubMed ID: 38878702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene transfer therapy in children with spinal muscular atrophy: A single-center experience with a cohort of 25 children.
    Chencheri N; Alexander G; Nugud A; Majadas E; Salim H; Prudhomme K; DeJager N; Janardhanan VS; Elbashir H
    Muscle Nerve; 2023 Sep; 68(3):269-277. PubMed ID: 37392188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacological and clinical profile of Onasemnogene Aveparvovec, the first gene therapy for spinal muscular atrophy (SMA)].
    Atsumi A; Yoneda T; Tsuchida K; Kagawa Y; Tominaga S; Kawase K; Kikuchi N
    Nihon Yakurigaku Zasshi; 2022; 157(1):53-61. PubMed ID: 34980814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.
    Mendell JR; Al-Zaidy S; Shell R; Arnold WD; Rodino-Klapac LR; Prior TW; Lowes L; Alfano L; Berry K; Church K; Kissel JT; Nagendran S; L'Italien J; Sproule DM; Wells C; Cardenas JA; Heitzer MD; Kaspar A; Corcoran S; Braun L; Likhite S; Miranda C; Meyer K; Foust KD; Burghes AHM; Kaspar BK
    N Engl J Med; 2017 Nov; 377(18):1713-1722. PubMed ID: 29091557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Experience With Gene Therapy in Older Patients With Spinal Muscular Atrophy.
    Matesanz SE; Battista V; Flickinger J; Jones JN; Kichula EA
    Pediatr Neurol; 2021 May; 118():1-5. PubMed ID: 33677142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polysomnography findings and respiratory muscle function in infants with early onset spinal muscular atrophy after gene replacement as monotherapy: A prospective study.
    Barrois R; Griffon L; Barnerias C; Gitiaux C; Desguerre I; Fauroux B; Khirani S
    Sleep Med; 2024 Jul; 119():335-341. PubMed ID: 38749258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy.
    Mendell JR; Al-Zaidy SA; Lehman KJ; McColly M; Lowes LP; Alfano LN; Reash NF; Iammarino MA; Church KR; Kleyn A; Meriggioli MN; Shell R
    JAMA Neurol; 2021 Jul; 78(7):834-841. PubMed ID: 33999158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Onasemnogene Abeparvovec in Type 1 Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis.
    Pascual-Morena C; Cavero-Redondo I; Lucerón-Lucas-Torres M; Martínez-García I; Rodríguez-Gutiérrez E; Martínez-Vizcaíno V
    Hum Gene Ther; 2023 Feb; 34(3-4):129-138. PubMed ID: 36136906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5 kg or Heavier in a Global Managed Access Program.
    Chand DH; Mitchell S; Sun R; LaMarca N; Reyna SP; Sutter T
    Pediatr Neurol; 2022 Jul; 132():27-32. PubMed ID: 35605311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination molecular therapies for type 1 spinal muscular atrophy.
    Harada Y; Rao VK; Arya K; Kuntz NL; DiDonato CJ; Napchan-Pomerantz G; Agarwal A; Stefans V; Katsuno M; Veerapandiyan A
    Muscle Nerve; 2020 Oct; 62(4):550-554. PubMed ID: 32710634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy.
    D'Silva AM; Holland S; Kariyawasam D; Herbert K; Barclay P; Cairns A; MacLennan SC; Ryan MM; Sampaio H; Smith N; Woodcock IR; Yiu EM; Alexander IE; Farrar MA
    Ann Clin Transl Neurol; 2022 Mar; 9(3):339-350. PubMed ID: 35170254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene replacement therapy for spinal muscular atrophy: safety and preliminary efficacy in a Brazilian cohort.
    Mendonça RH; Ortega AB; Matsui C; van der Linden V; Kerstenetzky M; Grossklauss LF; Silveira-Lucas EL; Polido GJ; Zanoteli E
    Gene Ther; 2024 Jul; 31(7-8):391-399. PubMed ID: 38839888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.
    Strauss KA; Farrar MA; Muntoni F; Saito K; Mendell JR; Servais L; McMillan HJ; Finkel RS; Swoboda KJ; Kwon JM; Zaidman CM; Chiriboga CA; Iannaccone ST; Krueger JM; Parsons JA; Shieh PB; Kavanagh S; Wigderson M; Tauscher-Wisniewski S; McGill BE; Macek TA
    Nat Med; 2022 Jul; 28(7):1390-1397. PubMed ID: 35715567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The respiratory impact of novel therapies for spinal muscular atrophy.
    Paul GR; Gushue C; Kotha K; Shell R
    Pediatr Pulmonol; 2021 Apr; 56(4):721-728. PubMed ID: 33098622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of gene therapy with onasemnogene abeparvovec in the treatment of spinal muscular atrophy: A systematic review and meta-analysis.
    Yang D; Ruan Y; Chen Y
    J Paediatr Child Health; 2023 Mar; 59(3):431-438. PubMed ID: 36722610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy.
    Lowes LP; Alfano LN; Arnold WD; Shell R; Prior TW; McColly M; Lehman KJ; Church K; Sproule DM; Nagendran S; Menier M; Feltner DE; Wells C; Kissel JT; Al-Zaidy S; Mendell J
    Pediatr Neurol; 2019 Sep; 98():39-45. PubMed ID: 31277975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.